With Phase III Failure, Cytokinetics Shelves Tirasemtiv, Pivots To ALS Backup

Partnered with Astellas, the San Francisco-area biotech hopes next-generation CK-107 will succeed in a measure of slow vital capacity due to stronger potency and better tolerability compared to tirasemtiv.